These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 22946342)

  • 1. Intra-arterial bevacizumab with blood brain barrier disruption in a glioblastoma xenograft model.
    Burkhardt JK; Santillan A; Hofstetter CP; Christos P; Berry N; Shin BJ; Foley CP; Gürsel DB; Ballon DJ; Gobin YP; Boockvar JA
    J Exp Ther Oncol; 2012; 10(1):31-7. PubMed ID: 22946342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Orthotopic glioblastoma stem-like cell xenograft model in mice to evaluate intra-arterial delivery of bevacizumab: from bedside to bench.
    Burkhardt JK; Hofstetter CP; Santillan A; Shin BJ; Foley CP; Ballon DJ; Pierre Gobin Y; Boockvar JA
    J Clin Neurosci; 2012 Nov; 19(11):1568-72. PubMed ID: 22985932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intra-arterial delivery of bevacizumab after blood-brain barrier disruption for the treatment of recurrent glioblastoma: progression-free survival and overall survival.
    Burkhardt JK; Riina H; Shin BJ; Christos P; Kesavabhotla K; Hofstetter CP; Tsiouris AJ; Boockvar JA
    World Neurosurg; 2012 Jan; 77(1):130-4. PubMed ID: 22405392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Durability of single dose intra-arterial bevacizumab after blood/brain barrier disruption for recurrent glioblastoma.
    Chakraborty S; Filippi CG; Burkhardt JK; Fralin S; Ray A; Wong T; Ortiz R; Langer DJ; Boockvar JA
    J Exp Ther Oncol; 2016 Nov; 11(4):261-267. PubMed ID: 27849336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repeated superselective intraarterial bevacizumab after blood brain barrier disruption for newly diagnosed glioblastoma: a phase I/II clinical trial.
    Patel NV; Wong T; Fralin SR; Li M; McKeown A; Gruber D; D'Amico RS; Patsalides A; Tsiouris A; Stefanov DG; Flores O; Zlochower A; Filippi CG; Ortiz R; Langer DJ; Boockvar JA
    J Neurooncol; 2021 Nov; 155(2):117-124. PubMed ID: 34601657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term benefit of intra-arterial bevacizumab for recurrent glioblastoma.
    Alter RA; White TG; Fanous AA; Chakraborty S; Filippi CG; Pisapia DJ; Tsiouris AJ; Boockvar JA
    J Exp Ther Oncol; 2017 May; 12(1):67-71. PubMed ID: 28472567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intra-arterial administration improves temozolomide delivery and efficacy in a model of intracerebral metastasis, but has unexpected brain toxicity.
    Muldoon LL; Pagel MA; Netto JP; Neuwelt EA
    J Neurooncol; 2016 Feb; 126(3):447-54. PubMed ID: 26694547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme.
    Lai A; Tran A; Nghiemphu PL; Pope WB; Solis OE; Selch M; Filka E; Yong WH; Mischel PS; Liau LM; Phuphanich S; Black K; Peak S; Green RM; Spier CE; Kolevska T; Polikoff J; Fehrenbacher L; Elashoff R; Cloughesy T
    J Clin Oncol; 2011 Jan; 29(2):142-8. PubMed ID: 21135282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost analysis of intra-arterial versus intra-venous delivery of bevacizumab for the treatment of recurrent glioblastoma multiforme.
    Burkhardt JK; Shin BJ; Schlaff CD; Riina H; Boockvar JA
    J Exp Ther Oncol; 2011; 9(3):183-6. PubMed ID: 22070049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temporary blood-brain barrier disruption by low intensity pulsed ultrasound increases carboplatin delivery and efficacy in preclinical models of glioblastoma.
    Dréan A; Lemaire N; Bouchoux G; Goldwirt L; Canney M; Goli L; Bouzidi A; Schmitt C; Guehennec J; Verreault M; Sanson M; Delattre JY; Mokhtari K; Sottilini F; Carpentier A; Idbaih A
    J Neurooncol; 2019 Aug; 144(1):33-41. PubMed ID: 31197598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rechallenging Recurrent Glioblastoma with Intra-Arterial Bevacizumab with Blood Brain-Barrier Disruption Results in Radiographic Response.
    Faltings L; Kulason KO; Patel NV; Wong T; Fralin S; Li M; Schneider JR; Filippi CG; Langer DJ; Ortiz R; Boockvar JA
    World Neurosurg; 2019 Nov; 131():234-241. PubMed ID: 31351210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Superselective intra-arterial cerebral infusion of novel agents after blood-brain disruption for the treatment of recurrent glioblastoma multiforme: a technical case series.
    Shin BJ; Burkhardt JK; Riina HA; Boockvar JA
    Neurosurg Clin N Am; 2012 Apr; 23(2):323-9, ix-x. PubMed ID: 22440875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of convection-enhanced delivery of bevacizumab on survival of glioma-bearing animals.
    Wang W; Sivakumar W; Torres S; Jhaveri N; Vaikari VP; Gong A; Howard A; Golden EB; Louie SG; Schönthal AH; Hofman FM; Chen TC
    Neurosurg Focus; 2015 Mar; 38(3):E8. PubMed ID: 25727230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of combined bevacizumab and intraperitoneal carboplatin or paclitaxel therapy in a mouse model of ovarian cancer.
    Shah DK; Veith J; Bernacki RJ; Balthasar JP
    Cancer Chemother Pharmacol; 2011 Oct; 68(4):951-8. PubMed ID: 21305289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor effect of NK012, a 7-ethyl-10-hydroxycamptothecin-incorporating polymeric micelle, on U87MG orthotopic glioblastoma in mice compared with irinotecan hydrochloride in combination with bevacizumab.
    Kuroda J; Kuratsu J; Yasunaga M; Koga Y; Kenmotsu H; Sugino T; Matsumura Y
    Clin Cancer Res; 2010 Jan; 16(2):521-9. PubMed ID: 20068081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Super selective intra-arterial cerebral infusion of modern chemotherapeutics after blood-brain barrier disruption: where are we now, and where we are going.
    D'Amico RS; Khatri D; Reichman N; Patel NV; Wong T; Fralin SR; Li M; Ellis JA; Ortiz R; Langer DJ; Boockvar JA
    J Neurooncol; 2020 Apr; 147(2):261-278. PubMed ID: 32076934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apparent diffusion coefficient changes predict survival after intra-arterial bevacizumab treatment in recurrent glioblastoma.
    Galla N; Chiang G; Chakraborty S; Singh R; John Tsiouris A; Boockvar J; Kovanlikaya I
    Neuroradiology; 2017 May; 59(5):499-505. PubMed ID: 28343250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. World's first delivery of intra-arterial bevacizumab directly into brain tumor of glioblastoma multiforme patients.
    Expert Rev Anticancer Ther; 2010 Jan; 10(1):5. PubMed ID: 20014880
    [No Abstract]   [Full Text] [Related]  

  • 19. Enhanced delivery improves the efficacy of a tumor-specific doxorubicin immunoconjugate in a human brain tumor xenograft model.
    Remsen LG; Trail PA; Hellström I; Hellström KE; Neuwelt EA
    Neurosurgery; 2000 Mar; 46(3):704-9. PubMed ID: 10719867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Republished: Real-time MRI guidance for intra-arterial drug delivery in a patient with a brain tumor: technical note.
    Zawadzki M; Walecki J; Kostkiewicz B; Kostyra K; Pearl MS; Solaiyappan M; Walczak P; Janowski M
    J Neurointerv Surg; 2019 Aug; 11(8):e3. PubMed ID: 31123186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.